THC Biomed Intl Ltd.
THCBF · OTC
7/31/2022 | 7/31/2021 | 7/31/2020 | 7/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.00 | 1.96 | 0.15 |
| FCF Yield | -21.98% | -8.43% | -4.18% | -36.55% |
| EV / EBITDA | -6.51 | -3.96 | 27.54 | -2.27 |
| Quality | ||||
| ROIC | -30.50% | -46.11% | 1.16% | -28.00% |
| Gross Margin | -42.03% | -84.10% | 77.64% | 100.86% |
| Cash Conversion Ratio | 0.61 | 0.16 | -0.71 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.30% | 36.33% | 65.28% | 191.93% |
| Free Cash Flow Growth | -43.76% | -6.97% | 85.46% | -19.28% |
| Safety | ||||
| Net Debt / EBITDA | -0.90 | -0.60 | 1.68 | -0.21 |
| Interest Coverage | -5.41 | -14.07 | 0.57 | -48.53 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 2.16 | 0.14 | -0.00 |
| Cash Conversion Cycle | 209.06 | 166.02 | 2,121.54 | -72,701.79 |